– UK, London – AstraZeneca PLC (LON: AZN / STO: AZN / Nasdaq: AZN) announced the appointments of Rene Haas and Birgit Conix to its Board as Non-Executive Directors with effect from 1 January 2025 and 1 February 2025 respectively.
Birgit Conix will join the Audit Committee.
Michel Demaré, Board Chair commented “I am confident Rene and Birgit will be excellent additions to the AstraZeneca Board. We look forward to welcoming them as we continue the process of refreshing the Board in anticipation of four current Non-Executive Directors reaching nine years’ tenure in the coming years. Rene brings deep and broad knowledge of technology including data science, computing and AI from his numerous years’ experience in the microprocessor, semiconductor and software engineering industry, and experience of leading a large Cambridge, UK-based technology company. Birgit’s financial and executive experience through successive CFO roles over the last decade, together with her 15 years’ experience of the pharmaceutical industry prior to that, will enable her to contribute to the Audit Committee’s and Board’s work from the outset. Both Rene and Birgit bring to AstraZeneca’s Board significant international experience in senior executive roles at large global businesses.”
About Rene Haas
Rene was appointed CEO and to the Arm Board in February 2022. In September 2023, he led Arm’s return to the public markets with the most valuable IPO of the year. Before becoming CEO, Rene was President of Arm’s IP Product Groups (IPG) from January 2017. Under his leadership, he transformed IPG to focus on key solutions for vertical markets with a more diversified product portfolio and increased investment in the Arm software ecosystem. Rene Haas joined Arm in October 2013 as VP of Strategic Alliances and two years later was appointed to the Executive Committee and named Arm’s CCO in charge of global sales and marketing.
Before joining Arm, Rene Haas held several applications management, applications engineering, and product engineering roles, including seven years at NVIDIA as VP and GM of its computing products business. Before NVIDIA, Rene held executive roles at Scintera Networks and Tensilica.
In addition to his role as CEO of Arm, Rene Haas also sits on the Boards of Arm China and SoftBank Group.
Rene Haas is based in Silicon Valley, US, and also spends significant time in the major technology centers of the UK, Europe, and Asia Pacific.
Rene Haas earned his Bachelor of Science in Electrical and Electronics Engineering from Clarkson University and is a graduate of the Stanford University Graduate School of Business Executive Education Program.
About Birgit Conix
Birgit Conix joined Sonova and became CFO and a member of the Management Board in 2021. She was previously CFO and member of the Executive Board of TUI, a global leader in tourism, from 2018 to 2021. Before joining TUI, she was CFO of the Belgian media, cable, and telecommunications business Telenet Group from 2013 until 2018. Before that, she held various senior positions in finance, strategy, and business operations in the pharmaceuticals and medical devices business units at Johnson & Johnson, and in finance at Heineken, Tennec,o and Reed Elsevier.
In addition to her role as CFO of Sonova, Birgit Conix is a member of the Supervisory Board of ASML, one of the world’s leading manufacturers of chip-making equipment in the semiconductor industry, where she is Chair of the ESG Committee, and a member of the Audit Committee.
Birgit Conix holds an MBA from the Booth School of Business, University of Chica, and a Master of Science in Business Economics from the University of Tilburg.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
For more: https://www.astrazeneca.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.